



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) International Patent Classification (IPC):
A61K 31/5377 ^(2006.01) **A61K 31/437** ^(2006.01)
A61K 31/4545 ^(2006.01) **A61P 27/00** ^(2006.01)
C07D 471/04 ^(2006.01) **A61P 11/14** ^(2006.01)

(48) Corrigendum issued on:
14.02.2024 Bulletin 2024/07

(52) Cooperative Patent Classification (CPC):
A61K 31/5377; A61K 31/437; A61K 31/4545;
A61P 11/14; A61P 27/00

(45) Date of publication and mention
of the grant of the patent:
03.01.2024 Bulletin 2024/01

(86) International application number:
PCT/IB2018/001513

(21) Application number: **18860273.4**

(87) International publication number:
WO 2019/064079 (04.04.2019 Gazette 2019/14)

(22) Date of filing: **14.09.2018**

(54) **SELECTIVE P2X3 ANTAGONISTS FOR USE IN TREATING CHRONIC COUGH WITHOUT LOSS OF TASTE RESPONSE**

SELEKTIVE P2X3-ANTAGONISTEN ZUR VERWENDUNG IN DER BEHANDLUNG CHRONISCHEN HUSTENS OHNE GESCHMACKSVERLUST

ANTAGONISTES SELECTIFS DE P2X3 POUR L'UTILISATION DANS LE TRAITEMENT DE LA TOUX CHRONIQUE SANS PERTE DE LA REPOSE GUSTATIVE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **18.09.2017 US 201762560077 P**
26.03.2018 US 201815936316

(43) Date of publication of application:
29.07.2020 Bulletin 2020/31

(60) Divisional application:
23219770.7

(73) Proprietor: **Bellus Health Inc.**
Laval, QC H7V 4A7 (CA)

(72) Inventors:
• **GARCEAU, Denis**
Laval, Québec H7V 4A7 (CA)
• **MATZOURANIS, Antonios**
Laval, Québec H7V 4A7 (CA)
• **BELLINI, Roberto**
Laval, Québec H7V 4A7 (CA)

• **PAYZA, Kemal**
Montreal, Québec H4S 1Z9 (CA)
• **CHAURET, Nathalie**
Laval, Québec H7V 4A7 (CA)
• **BROWNE, Susan, E.**
Christiana, PA 17509 (US)

(74) Representative: **Ahern, Jenna Marie**
GlaxoSmithKline
Global Patents, CN925.1
980 Great West Road
Brentford, Middlesex TW8 9GS (GB)

(56) References cited:
WO-A1-2018/064135 CA-A1- 2 777 746
CA-A1- 2 898 665 CA-A1- 2 921 395
CA-A1- 2 998 742

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- GARCEAU DENIS ET AL: "BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration", PULMORNARY PHARMACOLOGY & THERAPEUTICS, vol. 56, 20 March 2019 (2019-03-20), pages 56-62, XP085686664, ISSN: 1094-5539, DOI: 10.1016/J.PUPT.2019.03.007
- VANDENBEUCH AURELIE ET AL: "Postsynaptic P2X3?containing receptors in gustatory nerve fibres mediate responses to all taste qualities in mice", THE JOURNAL OF PHYSIOLOGY, vol. 593, no. 5, 1 March 2015 (2015-03-01) , pages 1113-1125, XP055830288, GB ISSN: 0022-3751, DOI: 10.1113/jphysiol.2014.281014
- BONVINI SARA J ET AL: "Cough and airway disease: The role of ion channels", PULMORNARY PHARMACOLOGY & THERAPEUTICS, ACADEMIC PRESS, GB, vol. 47, 29 June 2017 (2017-06-29), pages 21-28, XP085251864, ISSN: 1094-5539, DOI: 10.1016/J.PUPT.2017.06.009
- CHUNG KIAN FAN ED - CAZZOLA MARIO: "Advances in mechanisms and management of chronic cough: The Ninth London International Cough Symposium 2016", PULMORNARY PHARMACOLOGY & THERAPEUTICS, ACADEMIC PRESS, GB, vol. 47, 16 February 2017 (2017-02-16), pages 2-8, XP085251862, ISSN: 1094-5539, DOI: 10.1016/J.PUPT.2017.02.003